

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

Name of the Issue: **Vijaya Diagnostic Centre Limited**

- | | |
|---|--|
| 1. Type of Issue (IPO/FPO) | IPO |
| 2. Issue Size (Rs. Cr) | INR 1894.256 Cr |
| 3. Grade of issue along with name of the rating agency | |
| Name | NA |
| Grade | NA |
| 4. Subscription Level (Number of times) | 4.24861 (excluding Anchor Investor Portion and after removing multiple and duplicate bids and technical rejections cases) |

Source – Minutes of Basis of Allotment dated September 08, 2021

5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	Percentage
(i) allotment in the issue	21.78%*
(ii) at the end of the 1st Quarter immediately after the listing of the issue ^{^^}	39.25%
(iii) at the end of 1st FY (March 31, 2022) [#]	41.20%
(iv) at the end of 2nd FY (March 31, 2023) ^{##}	39.18%
(v) at the end of 3rd FY (March 31, 2024) ^{###}	40.89%

(*) As a % of total paid up capital as per prospectus dated September 06, 2021

(^{^^}) Source – Shareholding Pattern for the quarter ended September 30, 2021

([#]) Source – Shareholding Pattern for the quarter ended March 31, 2022

(^{##}) Source – Shareholding Pattern for the quarter ended March 31, 2023

(^{###}) Source – Shareholding Pattern for the quarter ended March 31, 2024

6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)

Consolidated

(Rs in Crores)

Parameters	1st FY (March 31, 2022)@	2nd FY (March 31, 2023)#	3rd FY (March 31, 2024)##
Income from operations	450.88	459.22	547.80
Net Profit for the period	108.10	85.20	119.64
Paid-up equity share capital	10.20	10.20	10.23
Reserves excluding revaluation reserves	459.78	534.52	646.96

@ Source – Audited Financials Results for the year ended March 31, 2022

Source – Audited Financials Results for the year ended March 31, 2023

Source – Audited Financials Results for the year ended March 31, 2024

7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both the BSE Limited and the National Stock Exchange of India Limited.

Particulars	Status
(i) at the end of 1st FY (March 31, 2022)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2023)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2024)	Frequently Traded

Source : Stock Exchange.

8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)	Mr. Nishant Sharma	Ceased to be Non-Executive Nominee Director w.e.f. March 7, 2022
(ii) at the end of 2nd FY (March 31, 2023)	None	None
(iii) at the end of 3rd FY (March 31, 2024)	Ms. Sura Suprita Reddy	Appointment as the Additional Director in the category of Managing Director & Chief Executive Officer (MD & CEO) of the company for a period of Five (5) consecutive years with effect from 01st July 2023 to 30th June 2028

Changes in the Board of Directors have been updated until September 14, 2024

9. Status of implementation of project/ commencement of commercial production

- (i) As disclosed in the offer document: NA
- (ii) Actual implementation: NA
- (iii) Reasons for delay in implementation, if any: NA

10. Status of utilization of issue proceeds

- (i) As disclosed in the offer document: NA
- (ii) Actual utilization: NA
- (iii) Reasons for deviation, if any: NA

11. Comments of monitoring agency, if applicable

(a) Comments on use of funds	Not Applicable as the Offer is an offer for the sale of Equity Shares, the Company will not receive any proceeds from the Offer. Accordingly, no monitoring agency is appointed for the Offer
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

12. Pricing Data

Issue Price (Rs.):	531
Designated Stock Exchange:	NSE
Listing Date:	September 14, 2021

Price parameters	At close of listing day (i.e. September 14, 2021)	At close of 30th calendar day from listing day (i.e. October 13, 2021)	At close of 90th calendar day from listing day (i.e. December 10, 2021)\$	As at the end of 1st FY after the listing of the issue (March 31, 2022)		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (NSE)	620.10	559.75	573.9	438.15	672	373.8
NIFTY50	17,380.00	18,161.75	17511.3	17464.75	18604.45	15671.45
Sectoral Index	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2023)			As at the end of 3rd FY after the listing of the issue (March 31, 2024)		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (NSE)	391.3	528	295	636.60	718.80	349.25
NIFTY50	17359.75	18887.60	15183.40	22326.90	22526.60	17312.75
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: NSE website

\$ The 90th calendar day from listing day (December 12, 2021) is a Sunday, therefore previous trading day, i.e. December 10, 2021 is considered

13. **Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)**

Accounting ratio		As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2022) ⁽²⁾	At the end of 2nd FY (March 31, 2023) ⁽³⁾	At the end of 3rd FY (March 31, 2024) ⁽⁴⁾
EPS	Issuer:	--	--	--	--
	Consolidated (Basic)	8.26	10.6	8.29	11.62
	Consolidated (Diluted)	8.26	10.54	8.26	11.59
	Peer Group :	--	--	--	--
	Dr. Lal Path Labs Limited	Basic: 35.33 Diluted: 35.25	Basic - 41.7 Diluted - 41.57	Basic - 28.82 Diluted - 28.74	Basic - 43.05 Diluted - 42.98
	Metropolis Healthcare Limited	Basic: 35.97 Diluted: 35.79	Basic - 37.52 Diluted - 37.34	Basic - 27.91 Diluted - 27.81	Basic - 24.95 Diluted - 24.87
	Industry Avg:	N.A	N.A	N.A	N.A
P/E	Issuer:	--	--	--	--

	Consolidated (Basic)	64.29	41.30	47.20	54.78
	Consolidated (Diluted)	64.29	41.53	47.37	54.93
	Peer Group:	--	--	--	--
	Dr. Lal Path Labs Limited	107.3	62.52	63.42	52.56
	Metropolis Healthcare Limited	74.4	54.28	44.75	69.19
	Industry Composite:	90.8	N.A	N.A	N.A
RoNW (%)	Issuer:	--	--	--	--
	Consolidated	23.64%	23.00%	15.64%	18.20%
	Peer Group:	--	--	--	--
	Dr. Lal Path Labs Limited	23.42%	23.23%	14.47%	19.59%
	Metropolis Healthcare Limited	25.91%	22.12%	14.51%	11.72%
	Industry Composite:	N.A	N.A	N.A	N.A
NAV	Issuer:	--	--	--	--
	Consolidated	35.23	46.09	53.37	64.24
	Peer Group:	--	--	--	--
	Dr. Lal Path Labs Limited	149.38	181.03	199.80	221.47
	Metropolis Healthcare Limited	138.23	169.61	192.97	213.88

	Industry Avg:	N.A	N.A	N.A	N.A
--	---------------	-----	-----	-----	-----

Notes:

- (1) Prospectus dated September 06, 2021
- (2) Source – Financial Results for the year ended March 31, 2022
- (3) Source – Financial Results for the year ended March 31, 2023
- (4) Source – Financial Results for the year ended March 31, 2024

Other Notes:

- All the financial information for listed industry peer mentioned above is on a consolidated basis and is sourced from the annual audited financial results of the company for the year ended March 31, 2021
- Vijaya Diagnostic Centre Limited has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the equity shares of face value of ₹10 each to Equity Shares of face value of ₹1 each. Further subsequent to March 31, 2021, pursuant to a Board resolution dated May 26, 2021 and Shareholders resolution dated May 26, 2021, our Company has capitalised the securities premium account to issue bonus Equity Shares in the ratio of 5 Equity Shares for every 4 Equity Shares held. Basic and diluted EPS are considered post sub-division and bonus issue.
- P/E Ratio for listed peers has been computed based on the closing market price of equity shares on BSE on August 11, 2021, divided by the Basic EPS.
- Net Profit is the Profit for the year attributable to equity shareholders of the Company
- Return on net worth %: Profit for the year attributable to equity shareholders of the Company divided by net worth as attributable to equity shareholders of the Company at the end of the year
- Net worth has been computed as sum of paid-up share capital and other equity.
- NAV is computed as the closing net worth divided by the closing outstanding number of equity shares. Vijaya Diagnostic Centre Limited has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the equity shares of face value of ₹10 each to Equity Shares of face value of ₹1 each. Further subsequent to March 31, 2021, pursuant to a Board resolution dated May 26, 2021 and Shareholders resolution dated May 26, 2021, bonus share has been issued in the ratio of 5 equity shares for every 4 equity shares. Net asset value per share is considered post sub-division and bonus issue

14. Any other material information

Particulars	Date
The Board of Directors of the Company at its meeting on November 8, 2021 has inter alia considered and approved the appointment of Ms.Anusha Kanumuru as Company Secretary and Compliance Officer w.e.f November 8, 2021 and took note of cessation of Ms.V.Sri Lakshmi as Company Secretary and Compliance Officer w.e.f November 8, 2021.	08-Nov-2021
The Company informed the Exchange regarding: Shifting of Registered Office of the Company from “3-6-16 & 17, Street No.19 Himayatnagar Hyderabad Telangana 500029” to “6-3-883/F,FPA Building, Near Topaz building, Punjagutta, Hyderabad Telangana 500082”, which is within the local limits of the city/town. The Board of the Company has taken note of the resignation submitted by Ms. Anusha Kanumuru, Company Secretary & Compliance Officer and she will be relieved from the services on or before December 31, 2022	10- Nov-2022

The Company has informed the exchange about the Appointment of Mr. Hansraj Singh, as Company Secretary of the Company.	13-Feb-2023
The Company has informed about the approval of the terms and conditions of the Share Purchase agreement (“SPA”) entered between the Company, P H Diagnostic Centre Private Limited (“P H / Target”) and its Promoters/Shareholders (“Sellers”) for the acquisition of 100% stake in “P H”.	19-Dec-2023
The Company has informed about the striking off Doctorslab Medical Services Private Limited (“Doctorslab”) a wholly owned subsidiary and Namrata Diagnostic Centre Private Limited (“Namrata”), step-down subsidiary of the Company (Non-functional and Non-material subsidiary) under Sec. 248(2) of the Companies Act, 2013 due to non-operations in the company for the past 3 years.	18-Jan-2024
The Company has informed about the approval given by Registrar of Companies(“ROC”) for striking off Doctorslab Medical Services Private Limited (“Doctorslab”) a wholly owned subsidiary and Namrata Diagnostic Centre Private Limited (“Namrata”), step-down subsidiary of the Company (Non-functional and Non-material subsidiary) under Sec. 248(2) of the Companies Act, 2013. Pursuant to the approval of ROC the said companies dissolved w.e.f. 6 th April, 2024.	8-April-2024
The Company has informed about the board approval for scheme of arrangement amongst the Company and Medinova Diagnostic Services Limited and their respective shareholders and creditors under Sections 230 to 232 and other applicable laws.	26-June-2024
The Company has informed about the resignation of Mr. Sheshadri Vasan, Chief Operating Officer of the Company has resigned from the services of the Company.	26-August-2024

Source- Stock Exchange Filings

All the above information has been updated till September 14, 2024 unless indicated otherwise